contact us  :   FAQs  :   site map  :   help  :   search  
Username Password   » Request Login 
  Home
  About ClearStream
  ClearStream Products
  Clinical Resources
  OEM Supply
  Distributors
  Investor Relations
  Careers
  Press Releases
  Latest News
Interactive Client Area

» Existing Customers 
» ClearStream Staff  
» Demonstration  
 

News
16 Aug 10
PMDA Approval in Japan for Sleek and Savvy Long Ca...

15 Jun 10
Holding(s) in Company...

View Current News »
View Archived News »

ClearStream Products     About ClearStream     Clinical Resources     Distributors     OEM Supply
» ClearStream Products  
  ClearStream Products
Quick Product Lookup
Trapidil Eluting Coronary DES
Delivery, efficacy, safety, stability


Intrepie Animation ImageProduct Animation:
Click here to view Intrepide Product Animation



Shipments of this product are temporarily suspended in line with ClearStream notice FSN003/13 August 2010, issued in accordance with MEDDEV 2.12-1 rev 6

Intrepide is a coronary DES, which elutes the drug Trapidil. The system is mounted on the Nimbus Pico rapid exchange catheter platform.

Trapidil has been shown in a number of clinical studies to demonstrate four primary modes of action when given orally:

  • Anti-proliferative

  • Vasodilator

  • Anti-thrombotic

  • Anti-inflammatory
Trapidil was initially developed in 1971 . The drug was initially designed as a vasodilator. However, over the past few decades, studies have found Trapidil to be a potent inhibitor of platelet aggregation and activation, vascular smooth muscle cell proliferation, and monocyte/macrophage migration and activation, thereby making it a
potentially potent anti-restenotic agent.

Product Features
Delivery - The Intrepide is mounted on our Nimbus Pico catheter, which allows for better access to the most complex lesions. The overall profile is the lowest of any DES currently on the market today.
Efficacy - Intrepide has four modes of action which are, anti-inflammatory, anti-thrombotic, anti-proliferative and acts as a vasodilator. These combined make Intrepide one of the most interesting DES developments since their first clinical introduction.
Safety - Results from the DESTINY I trial demonstrate that Product related MACE at 30 days is 0%, Target lesion revascularisation is 5.2% at 180 days and there was no Subacute Thrombosis at 180 days, making Intrepide one of the safest stents on the market
Stability - The Intrepide is a highly temperature stable drug, meaning that it can be used in any ambient atmosphere likely to be encountered in all climates.

Product Specification

Catheter specifications
Nominal pressure 2.5 - 4.0mm = 6Atm
Rated burst pressure 2.5 - 4.0mm = 16Atm (4.0 x >30mm balloon = 14Atm)
Average burst pressure 22Atm (4.0 x >30mm balloon = 20Atm)
Average compliance 10%
Average deflation time <7sec. for 3.0mm x 20mm catheter
Fold Trifold with memory
Tip Lead in Profile 0.018' (0.457mm)
Shaft
Overall catheter length 142cm (Usable catheter length 135cm)
Distal shaft material Pebax / Nylon
Distal shaft diameter
2.5 - 3.0mm balloon 2.7F
3.5 - 4.0mm balloon 2.8F
Rapid Exchange transition XXtraFlex™ Technology
Proximal shaft material Stainless steel hypotube with lubricious coating
Proximal shaft diameter 2.0F
Hub Polycarbonate with standard luer fitting
Guidewire Max. wire diameter 0.014" (0.355)
Marker Bands Swaged platinum iridium marker bands of length 1.0mm
Bar Coding EAN 128
Stent
Material 316L Stainless Steel
Mounted stent profile 2.5mm - 0.037"
2.75mm - 0.038"
3.0mm - 0.039"
3.5mm - 0.041"
4.0mm - 0.043"
Strut thickness 0.032"
Foreshortening <6%

 
 
Device Detail
Product Brochure
Order Information
 
 
Resources for Medical Practitioners
Case Studies
  Terms of Use   |   Contact ClearStream   |   Find Us
  © 2010 ClearStream  Technologies Group plc                   Moyne Upper, Enniscorthy, Co. Wexford, Ireland                   t: +353 (0)53 92 37111 Powered by WebPublish
Valid CSS!